 |
|
|
| |
Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues
|
| |
| |
Reported by Jules Levin
HIV Drug Therapy Conference, Glasgow, UK, November 2014
1Amanda Clarke, Brighton and Sussex Medical School, Brighton, United Kingdom 2. Veronika Johanssen, Karolinkska University, Sjukhuset, Sweden. 3. Jan Gerstoft, Copenhagen University Hospital, Copenhagen, Denmark 4. Clotet, Bonaventura University Hospital Germans Trias i Pujol, irsiCaixa, Badalona, Spain 5.Diego Ripamonti, University Hospital, Bergamo, Italy 6. Ceyhun Bicer, Janssen, Beerse, Belgium 7. Maria Blanca Hadacek, Janssen EMEA, Issy-les-Moulineaux, France 8. Christiane Moecklinghoff, Janssen EMEA, Neuss, Germany
|
| |
|
|
|
|
|
